Anavex Life Sciences

AVXLNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$228.961 M

$2.47 +2.92%

Close of 22 Sept 2026

Revenue

—

Not reported

Earnings

-$46.4M

Loss-making

Shares outstanding

89,348,107

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#89Lineage Cell TherapeuticsLCTX$263.0M
#90CompugenCGEN$235.5M
#91Anavex Life SciencesAVXL$229.0M
#92Protalix BioTherapeuticsPLX$228.8M
#93Cardiol TherapeuticsCRDL$228.0M

What if Anavex Life Sciences were worth as much as…

Open the what-if tool →

Gold $30.2T

$326,159.65

Per share 132,048× higher

Bitcoin $1.74T

$18,788.72

Per share 7,607× higher

Nvidia $5.52T

$59,503.29

Per share 24,090× higher

Or at a round number

$500.0M $1.00B $2.00B $5.00B

Where these numbers come from

Share counts and financials for Anavex Life Sciences are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.